Fifth, this study primarily focuses on the therapeutic effects of APG and the underlying mechanism involving ALDH1A2 during the early stages of ALS, without exploring the effects of APG treatment in the middle or late stages of the disease. This evidence concerns the gene ALDH1A2 and amyotrophic lateral sclerosis.